Disease · MONDO_0013662
Barrett esophagus
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Barrett esophagus. Diseases, record MONDO_0013662. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0013662
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
(ulcerative esophagitis) or (Barrett's esophagus), BE, Barrett Epithelium, Barrett Syndrome, Barrett esophagus/esophageal adenocarcinoma, Barrett's Syndrome, Barrett's esophagus, Barrett's esophagus (disorder), Barrett's esophagus (disorder) [Ambiguous], Barrett's esophagus with esophagitis (disorder), Barrett's oesophagus, Barrett's oesophagus with esophagitis, Barrett's ulcer of esophagus (disorder), Barrett's ulcer of oesophagus, Barretts Esophagus, Barretts syndrome, CELLO, CLE, Epithelium, Barrett, Esophagus, Barrett, Esophagus, Barrett's, Syndrome, Barrett, Syndrome, Barrett's, columnar epithelial-lined Lower esophagus, columnar epithelial-lined Lower oesophagus, columnar-lined esophagus, columnar-lined oesophagus
- Open Targets
- Highest stage of its drugs
- Approval, for 1 of its 20 drugs, from EMA Human Drugs, at withdrawal
- Open Targets
Drugs20
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PORFIMER SODIUM | CHEMBL1201481 | Small molecule | Approval | EMA Human Drugs, at withdrawal | 2 | 1 | 1 | Drugs and targets |
| PANTOPRAZOLE | CHEMBL1502 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RANITIDINE | CHEMBL1790041 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NETAZEPIDE | CHEMBL324547 | Protein | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ALGINIC ACID | CHEMBL2108894 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| HPPH | CHEMBL500853 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OBETICHOLIC ACID | CHEMBL566315 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ESOMEPRAZOLE | CHEMBL1201320 | Small molecule | Phase 1 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CANDESARTAN | CHEMBL1016 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CHOLECALCIFEROL | CHEMBL1042 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 20
See all 20 drugsTargets19
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ATP4A | Potassium-transporting ATPase | 3 | Potassium-transporting ATPase inhibitor | Phase 3 | https://conductscience.org/library/genes/495 | Drugs and targets |
| ATP4B | Potassium-transporting ATPase | 3 | Potassium-transporting ATPase inhibitor | Phase 3 | https://conductscience.org/library/genes/496 | Drugs and targets |
| NR1H4 | Bile acid receptor | 2 | Bile acid receptor FXR agonist | Phase 2 | https://conductscience.org/library/genes/9971 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 1 | Angiotensin-converting enzyme inhibitor | Early phase 1 | https://conductscience.org/library/genes/1636 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 1 | Type-1 angiotensin II receptor antagonist | Early phase 1 | https://conductscience.org/library/genes/185 | Drugs and targets |
| BRAF | Serine/threonine-protein kinase B-raf | 1 | Serine/threonine-protein kinase B-raf inhibitor | Unknown | https://conductscience.org/library/genes/673 | Drugs and targets |
| CCKBR | Gastrin/cholecystokinin type B receptor | 1 | Cholecystokinin B receptor antagonist | Phase 2 | https://conductscience.org/library/genes/887 | Drugs and targets |
| ESR1 | Estrogen receptor | 1 | Estrogen receptor alpha modulator | Early phase 1 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Unknown | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | 1 | Tyrosine-protein kinase receptor FLT3 inhibitor | Unknown | https://conductscience.org/library/genes/2322 | Drugs and targets |
1 to 10 of 19
See all 19 targetsTrials18
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00858858 | Clinical Studies on Bile Acids in Barrett's Esophagus | Not applicable | 60 | 2014-11-24 | Gastroesophageal Reflux Disease | DEOXYCHOLIC ACID, URSODIOL | Its record names the disease | ClinicalTrials.gov |
| NCT01129778 | Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus | Not applicable | 27 | 2017-06-06 | Barrett Esophagus, Gastroesophageal Reflux | MAGNESIUM HYDROXIDE, OMEPRAZOLE, SODIUM BICARBONATE | Its record names the disease | ClinicalTrials.gov |
| NCT01298999 | Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus | Phase 2 | 27 | 2021-11-23 | Barrett's Esophagus | NETAZEPIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02597712 | YF476 in Barrett's Esophagus | Phase 2 | 27 | 2021-04-12 | Barrett's Esophagus | NETAZEPIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03193216 | The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus | Phase 2 | 24 | 2023-03-08 | Barretts Esophagus With Dysplasia | ALGINIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT00619242 | The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer | Not applicable | 3 | 2013-10-21 | Esophageal Cancer | SORAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT04329000 | On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus. | Not applicable | 218 | Barrett Esophagus, Proton Pump Inhibitor, Symptom, Reflux | ESOMEPRAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT04154748 | Argon Plasma Coagulation for Barrett's Esophagus | Not applicable | 71 | Barretts Esophagus With Low Grade Dysplasia | OMEPRAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT00161200 | Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor | Phase 3 | 60 | Esophageal Metaplasia | PANTOPRAZOLE, RANITIDINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00281736 | Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer | Phase 2 | 60 | Esophageal Cancer, Precancerous Condition | HPPH | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 18
See all 18 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| YF476 vs Placebo: deaths from any cause | 0 of 13 | 0 of 11 | 24 | NCT01298999 | Trial comparisons |
| YF476 vs Placebo: serious adverse events | 1 of 13 | 0 of 11 | 24 | NCT01298999 | Trial comparisons |
| Treatment vs YF476 Placebo: deaths from any cause | 0 of 13 | 0 of 11 | 24 | NCT02597712 | Trial comparisons |
| Treatment vs YF476 Placebo: serious adverse events | 1 of 13 | 0 of 11 | 24 | NCT02597712 | Trial comparisons |
| YF476 vs Placebo: Number of Participants That Experienced Change in Any Biomarker Expression | 10 of 10 | 9 of 10 | 20 | NCT01298999 | Trial comparisons |
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0013662
GET https://conductscience.org/api/diseases/v1/MONDO_0013662/drugs